We and others reported that through various pathways and mechanisms, the expression and activity of eEF-2 kinase favors glioma cell survival and invasion [11,14,15] and modulates sensitivity of tumor cells to therapeutic agents such as deoxyglucose [16], velcade and curcumin [17], MK-2206 [18], and Trail [19]. The gene discussed is EEF2K; the disease is central nervous system cancer.